Comparison of Granulocyte Colony-Stimulating Factor (G-CSF)-Mobilized Peripheral Blood Progenitor Cells and G-CSF-Stimulated Bone Marrow as a Source of Stem Cells in HLA-Matched Sibling Transplantation

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 4 A, 2000, Pages 434-440

  Serody, Jonathan S ^a,c   Sparks, Scotty D ^b   Lin, Yuhua ^c   Capel, Eileen J ^a   Bigelow, Sharon H ^a   Kirby, Suzanne L ^a,c   Gabriel, Don A ^a   Wiley, Joseph M ^a   Brecher, Mark E ^b   Schell, Michael J ^c   Folds, James ^b   Shea, Thomas C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Allogeneic transplantation; G CSF; Graft versus host disease

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD CELL; BONE MARROW CELL; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; HUMAN; MIDDLE AGED; NEOPLASM; STEM CELL MOBILIZATION; SURVIVAL;

ADOLESCENT; ADULT; BLOOD CELLS; BONE MARROW CELLS; CHILD; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MIDDLE AGED; NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034564258     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70035-8     Document Type: Article

References (31)

1. Durrant ST, Morton AJ. A randomised trial of filgrastim (G-CSF) stimulated donor marrow (BM) versus peripheral blood (PBPC) for allogeneic transplantation: increased extensive chronic graft-versus-host disease following PBPC transplantation [abstract]. Blood. 1999;94:608a.
2. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659-1665.
3. Mahmoud HK, Fahmy O, Kamil M, El-Haddad A, El-Kadi D. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:355-358.
4. Pavletic ZS, Bishop MR, Tarantolo SR, et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997;15:1608-1616.
5. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim granulocyte colony-stimulating-factor. Blood. 1995;85:1666-1672.
6. Brown RA, Adkins D, Khoury H, et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol. 1999;17:806-812.
7. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705-4709.
8. Ustun C, Arslan O, Beksac M, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs-host disease and relapse. Biol Blood Marrow Transplant. 1999;5:28-35.
9. + cell content but is associated with delayed pancytopenia. Bone Marrow Transplant. 1998;21:431-440.
10. Janssen WE, Smilee RC, Elfenbein GJ. A prospective randomized trial comparing blood-and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother. 1995;4:139-140.
11. Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood. 1998;91:347-352.
12. Pan L, Delmonte J, Jalonen CK, Ferrara JL. Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.
13. Pan L, Teshima T, Hill GR, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 1999;93:4071-4078.
14. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood. 1998;92:215-222.
15. Serody JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am. 1997;11:459-477.
16. Santos GW. Busulfan and cyclophosphamide for marrow transplantation. Bone Marrow Transplant. 1989;4(suppl):236-239.
17. Bensinger WI, Buckner CD, Clift RA, et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol. 1992;10:1492-1497.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Bandarenko N, Brecher ME, Owen H, Wiley J, Shea T, Serody J. Thrombocytopenia in allogeneic peripheral blood stem cell collections. Transfusion. 1996;36:668-669.
21. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996;88:2794-2800.
22. Gondo H, Harada M, Taniguchi S, et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant. 1993;12:437-441.
23. von Bueltzingsloewen A, Belanger R, Perreault C, et al. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood. 1993;81:849-855.
24. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094-1101.
25. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporine compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol. 1989;72:567-572.
26. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729-1734.
27. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882-1891.
28. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998;102:115-123.
29. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
30. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465-1470.
31. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant. 1997;20:1033-1037.